Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1716 ARTÍCULOS , VIENDO DEL 1591 AL 1605

Cognitive Impairment in Older Adults and Therapeutic Strategies

Montine TJ, Bukhari SA, White LR.

Pharmacol Rev. 2021 Jan;73(1):152-162. doi: 10.1124/pharmrev.120.000031.

Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route

Dali P, Shende P.

Curr Pharm Biotechnol. 2021;22(11):1466-1481. doi: 10.2174/1389201021666201218130947.

Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases

Mayo S, Benito-León J, Peña-Bautista C, Baquero M, Cháfer-Pericás C.

Curr Neuropharmacol. 2021;19(8):1273-1303. doi: 10.2174/1570159X19666201223154009.

Environmental exposures and the etiopathogenesis of Alzheimer's disease: The potential role of BACE1 as a critical neurotoxic target

Syeda T, Cannon JR.

J Biochem Mol Toxicol. 2021 Apr;35(4):e22694. doi: 10.1002/jbt.22694. Epub 2021 Jan 4.

Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times

Nabavi SM, Sobarzo-Sánchez E.

Curr Neuropharmacol. 2021;19(2):112-113. doi: 10.2174/1570159X1902201231153120.

The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models

MacDougall G, Brown LY, Kantor B, Chiba-Falek O.

Mol Ther. 2021 Mar 3;29(3):949-972. doi: 10.1016/j.ymthe.2021.01.001. Epub 2021 Jan 9.

GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment

Pal D, Mukherjee S, Song IH, Nimse SB.

Curr Drug Targets. 2021;22(15):1725-1737. doi: 10.2174/1389450122666210114095307.

Defining the Neuropathological Aggresome across in Silico, in Vitro, and ex Vivo Experiments

Gomes GN, Levine ZA.

J Phys Chem B. 2021 Mar 4;125(8):1974-1996. doi: 10.1021/acs.jpcb.0c09193. Epub 2021 Jan 19.

Deep Brain Stimulation in Alzheimer's Disease: Targeting the Nucleus Basalis of Meynert

Chen YS, Shu K, Kang HC.

J Alzheimers Dis. 2021;80(1):53-70. doi: 10.3233/JAD-201141.

Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders

Saha S, Pal D, Nimse SB.

Curr Drug Targets. 2021;22(12):1437-1462. doi: 10.2174/1389450122666210120143953.

Editorial to the Special Issue "Lipidomics and Neurodegenerative Diseases"

Calvano CD, Losito I, Cataldi T.

Int J Mol Sci. 2021 Jan 28;22(3):1270. doi: 10.3390/ijms22031270.

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer's and Parkinson's Disease

Lee JH, Kim HJ, Kim JU, Yook TH, Kim KH, Lee JY, Yang G.

Int J Mol Sci. 2021 Jan 28;22(3):1324. doi: 10.3390/ijms22031324.

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C.

Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2.

An autopsy case of corticobasal syndrome due to asymmetric degeneration of the motor cortex and substantia nigra with TDP-43 proteinopathy, associated with Alzheimer's disease pathology

Tando S, Kasai T, Mizuta I, Takahashi H, Yaoi T, Saito K, Hojo T, Mizuno T, Hasegawa M, Itoh K.

Neuropathology. 2021 Jun;41(3):214-225. doi: 10.1111/neup.12723. Epub 2021 Feb 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias